Sponsored content brought to you by

Isoplexis logo

Limitations in Current Treatment Landscape for NSCLCs

PD-1 immune checkpoint inhibitors have made significant advancements in treating metastatic lung cancer, but still present several challenges. Even when coupled with chemotherapy, patients may continue to experience cancer progression. While researchers continue to discover new immune checkpoint combinations, clinical results have been mixed.1 Treatment options for non-small cell lung cancers (NSCLCs) can be especially challenging due to their shortage of activated, tumor-specific T cells. To combat this, researchers are using adoptive cell therapy (ACT) to provide patients with a large influx of T cells with tumor specificity. Tumor-infiltrating lymphocytes (TILs) that are cultured from a patient’s tumor have shown durable responses in a subset of patients with metastatic melanoma. Given this success, researchers have conducted a single-arm open-label Phase I trial of TILs administered with nivolumab in patients with advanced NSCLC following initial progression on nivolumab monotherapy.1 The team recently published its work in Nature Medicine.

Product Quality Metrics for Treatment of Metastatic Lung Cancer with TILs

The team used IsoPlexis’ platform in this Phase I trial, demonstrating the power of IsoPlexis’ single-cell functional phenotyping, as it provided a predictive metric for potency and persistence in TIL therapies. The polyfunctional strength index (PSI) was used to measure the ability of single T cells to secrete multiple different cytokines after stimulation. PSI is an indicator of the number of cells capable of secreting multiple types of cytokines and reflects the ability of a T cell to carry out multiple functions. The IsoPlexis platform’s functional readouts have been shown to be critical for understanding the potency and durability of cell therapies.

This is just one example that showcases the power of IsoPlexis’ unique biology, as it helps researchers advance TIL therapies and other cell therapies by providing predictive quality metrics. By allowing researchers to evaluate product potency, predict patient response, and identify top therapeutic candidates on one integrated, walk-away automated platform,
IsoPlexis fills a critical need in the field.

To learn more about recent advances in cell and immunotherapies for cancer, and the role single-cell proteomics plays in the growth of this groundbreaking field, visit our website.

 

Learn more isoplexis.com

 

Reference

  1. Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 2021; 27: 1410–1418.
Previous articleCasting a Wider Net: How Spatial Omics Leads to New Discoveries
Next articleThree Key Factors Affecting Single-Cell Transcriptional Analysis